You’re conflating market price with scientific mechanism and regulatory trajectory.
Yes, the share price is under pressure. That’s what happens when regulatory timelines stretch, short interest spikes, and uncertainty dominates. But price doesn’t invalidate mechanism. It doesn’t erase clinical data. And it damn sure doesn’t negate NHS placement of DCVax-L on the High Cost Drug list.
If you want to argue valuation, that's fine. But don’t pretend that quoting the current SP is a rebuttal to the science behind DCVax-L or the regulatory framing that’s already in motion.
And for the record—I never said approval for tissue agnosticism was guaranteed, or that lawsuits or squeezes would net billions. That’s your strawman. What I did say is that DCVax-L’s mechanism is agnostic by design, and the NHS has already validated that broader potential. The question is when regulators will formally expand the label—not whether the science supports it.
If you want to talk data, mechanism, or regulatory precedent, I’m here. If you just want to vent about price, that’s fine too. But don’t confuse one for the other.
Market Data 
Markets 
